A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT
  • Sponsors Eisai Inc
  • Most Recent Events

    • 23 Feb 2017 Results of exploratory analysis assessing efficacy of Lenvatinib published in the European Journal of Cancer.
    • 11 Oct 2016 Results of sub-analysis assessing responses in specific metastases in patients treated with lenvatinib presented at the 41st European Society for Medical Oncology Congress.
    • 06 Oct 2016 According to Eisai media release, subanalyses from this study was presented at the European Society for Medical Oncology (ESMO) Congress 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top